Recursion Pharmaceuticals (RXRX) EBT (2020 - 2026)

Recursion Pharmaceuticals (RXRX) has 7 years of EBT data on file, last reported at -$122.1 million in Q1 2026.

• Quarterly EBT rose 39.74% year-over-year to -$122.1 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$564.4 million (up 1.9% YoY) and the FY2025 annual result came in at -$644.9 million, down 38.75% from the prior year.
• EBT retreated to -$122.1 million in Q1 2026, from -$108.1 million in the prior quarter.
• In the past five years, EBT ranged from a high of -$56.0 million in Q1 2022 to a low of -$202.6 million in Q1 2025.
• A 5-year average of -$106.9 million and a median of -$95.7 million in 2024 frame the typical range for EBT.
• Annual changes were most pronounced in 2025 — EBT tumbled 119.9% — and 2026, when it soared 39.74%.
• Tracing RXRX's EBT over 5 years: stood at -$68.0 million in 2022, then slumped by 42.63% to -$97.1 million in 2023, then slumped by 84.32% to -$178.9 million in 2024, then surged by 39.57% to -$108.1 million in 2025, then dropped by 12.96% to -$122.1 million in 2026.
• The last three EBT figures came in at -$122.1 million (Q1 2026), -$108.1 million (Q4 2025), and -$162.2 million (Q3 2025), per Business Quant data.